Literature DB >> 17409445

Induction of Cdc25B regulates cell cycle resumption after genotoxic stress.

Pallavi Bansal1, John S Lazo.   

Abstract

Cdc25 phosphatases propel cell cycle progression by activating cyclin-dependent kinases (Cdk). DNA damage is generally thought to inhibit Cdc25 functionality by inducing proteasomal degradation of Cdc25A and phosphorylation-mediated sequestration of Cdc25B and Cdc25C to the cytoplasm. More recently, a critical role for Cdc25B in the resumption of cell cycle progression through mitosis after DNA damage has been identified. In this study, the fate of Cdc25B after mechanistically distinct DNA-damaging agents (etoposide, cisplatin, bleomycin, ionizing irradiation, or UV irradiation) was examined, and surprisingly a rapid increase in cellular Cdc25B levels was observed after DNA damage. Using UV irradiation as the prototypic damaging agent, we found that the increase in Cdc25B levels was checkpoint dependent and was controlled by a p53-independent mechanism. Cdc25B levels controlled the number of cells progressing into mitosis after UV, but they did not affect G(2)-M checkpoint engagement immediately after DNA damage. Increased Cdc25B reduced the time required for cell cycle resumption. These data support a model in which Cdc25B accumulation is an important anticipatory event for cell cycle resumption after DNA damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409445     DOI: 10.1158/0008-5472.CAN-06-3685

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Multimodal control of Cdc25A by nitrosative stress.

Authors:  Robert J Tomko; John S Lazo
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

2.  Carboxy-terminal phosphorylation sites in Cdc25 contribute to enforcement of the DNA damage and replication checkpoints in fission yeast.

Authors:  Corey Frazer; Paul G Young
Journal:  Curr Genet       Date:  2012-07-18       Impact factor: 3.886

Review 3.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

4.  Identification of survival genes in human glioblastoma cells by small interfering RNA screening.

Authors:  Nikhil G Thaker; Fang Zhang; Peter R McDonald; Tong Ying Shun; Michael D Lewen; Ian F Pollack; John S Lazo
Journal:  Mol Pharmacol       Date:  2009-09-25       Impact factor: 4.436

5.  Unscheduled expression of CDC25B in S-phase leads to replicative stress and DNA damage.

Authors:  Béatrix Bugler; Estelle Schmitt; Bernadette Aressy; Bernard Ducommun
Journal:  Mol Cancer       Date:  2010-02-04       Impact factor: 27.401

6.  Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.

Authors:  Zhihui Wang; Claes G Trope; Vivi Ann Flørenes; Zhenhe Suo; Jahn M Nesland; Ruth Holm
Journal:  BMC Cancer       Date:  2010-05-25       Impact factor: 4.430

7.  Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.

Authors:  Paul A Johnston; Caleb A Foster; Marni Brisson Tierno; Tong Ying Shun; Sunita N Shinde; William D Paquette; Kay M Brummond; Peter Wipf; John S Lazo
Journal:  Assay Drug Dev Technol       Date:  2009-06       Impact factor: 1.738

8.  Radiation Sensitivity and Tumor Susceptibility in ATM Phospho-Mutant ATF2 Mice.

Authors:  Shuangwei Li; Sergei Ezhevsky; Antimone Dewing; Matthew H Cato; Marzia Scortegagna; Anindita Bhoumik; Wolfgang Breitwieser; Demetrious Braddock; Alexey Eroshkin; Jianfei Qi; Meifan Chen; Jae-Young Kim; Stephen Jones; Nic Jones; Robert Rickert; Ze'ev A Ronai
Journal:  Genes Cancer       Date:  2010-04-01

9.  Artemis regulates cell cycle recovery from the S phase checkpoint by promoting degradation of cyclin E.

Authors:  Haiyong Wang; Xiaoshan Zhang; Liyi Geng; Lisong Teng; Randy J Legerski
Journal:  J Biol Chem       Date:  2009-05-07       Impact factor: 5.157

10.  MAPK pathway activation delays G2/M progression by destabilizing Cdc25B.

Authors:  Puji Astuti; Tanya Pike; Charlotte Widberg; Elizabeth Payne; Angus Harding; John Hancock; Brian Gabrielli
Journal:  J Biol Chem       Date:  2009-10-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.